Winter cholecalciferol supplementation at 51°N has no effect on markers of cardiometabolic risk in healthy adolescents aged 14-18 years

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Winter cholecalciferol supplementation at 51°N has no effect on markers of cardiometabolic risk in healthy adolescents aged 14-18 years. / Smith, Taryn J; Tripkovic, Laura; Hauger, Hanne; Damsgaard, Camilla Trab; Mølgaard, Christian; Lanham-New, Susan A; Hart, Kathryn H.

I: Journal of Nutrition, Bind 148, Nr. 8, 2018, s. 1269-1275.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Smith, TJ, Tripkovic, L, Hauger, H, Damsgaard, CT, Mølgaard, C, Lanham-New, SA & Hart, KH 2018, 'Winter cholecalciferol supplementation at 51°N has no effect on markers of cardiometabolic risk in healthy adolescents aged 14-18 years', Journal of Nutrition, bind 148, nr. 8, s. 1269-1275. https://doi.org/10.1093/jn/nxy079

APA

Smith, T. J., Tripkovic, L., Hauger, H., Damsgaard, C. T., Mølgaard, C., Lanham-New, S. A., & Hart, K. H. (2018). Winter cholecalciferol supplementation at 51°N has no effect on markers of cardiometabolic risk in healthy adolescents aged 14-18 years. Journal of Nutrition, 148(8), 1269-1275. https://doi.org/10.1093/jn/nxy079

Vancouver

Smith TJ, Tripkovic L, Hauger H, Damsgaard CT, Mølgaard C, Lanham-New SA o.a. Winter cholecalciferol supplementation at 51°N has no effect on markers of cardiometabolic risk in healthy adolescents aged 14-18 years. Journal of Nutrition. 2018;148(8):1269-1275. https://doi.org/10.1093/jn/nxy079

Author

Smith, Taryn J ; Tripkovic, Laura ; Hauger, Hanne ; Damsgaard, Camilla Trab ; Mølgaard, Christian ; Lanham-New, Susan A ; Hart, Kathryn H. / Winter cholecalciferol supplementation at 51°N has no effect on markers of cardiometabolic risk in healthy adolescents aged 14-18 years. I: Journal of Nutrition. 2018 ; Bind 148, Nr. 8. s. 1269-1275.

Bibtex

@article{37982023e60046368ed1bd41c3ae9845,
title = "Winter cholecalciferol supplementation at 51°N has no effect on markers of cardiometabolic risk in healthy adolescents aged 14-18 years",
abstract = "Background: Epidemiologic studies have supported inverse associations between low serum 25-hydroxyvitamin D [25(OH)D] and cardiometabolic risk markers, but few randomized trials have investigated the effect of vitamin D supplementation on these markers in adolescents.Objective: The objective of this study was to investigate the effect of winter-time cholecalciferol (vitamin D3) supplementation on cardiometabolic risk markers in white, healthy 14- to 18-y-old adolescents in the UK (51°N) as part of the ODIN Project.Methods: In a dose-response trial, 110 adolescents (mean ± SD age: 15.9 ± 1.4 y; 43% male; 81% normal weight) were randomly assigned to receive 0, 10 or 20 μg/d vitamin D3 for 20 wk (October-March). Cardiometabolic risk markers including BMI-for-age z score (BMIz), waist circumference, systolic and diastolic blood pressure, fasting plasma triglycerides, cholesterol (total, HDL, LDL, and total:HDL), and glucose were measured at baseline and endpoint as secondary outcomes, together with serum 25(OH)D. Intervention effects were evaluated in linear regression models as between-group differences at endpoint, adjusted for the baseline value of the outcome variable and additionally for age, sex, Tanner stage, BMIz, and baseline serum 25(OH)D.Results: Mean ± SD baseline serum 25(OH)D was 49.1 ± 12.3 nmol/L and differed between groups at endpoint with concentrations of 30.7 ± 8.6, 56.6 ± 12.4, and 63.9 ± 10.6 nmol/L in the 0, 10, and 20 μg/d groups, respectively (P ≤ 0.001). Vitamin D3 supplementation had no effect on any of the cardiometabolic risk markers (all P > 0.05), except for lower HDL (-0.12 mmol/L; 95% CI: -0.21, 0.04 mmol/L; P = 0.003) and total cholesterol (-0.21 mmol/L; 95% CI: -0.42, 0.00 mmol/L; P = 0.05) in the 20 μg/d than in the 10 μg/d group, which disappeared in the fully adjusted analysis (P = 0.27 and P = 0.30, respectively).Conclusions: Supplementation with vitamin D3 at 10 and 20 μg/d, which increased serum 25(OH)D concentrations during the winter-time, had no effect on markers of cardiometabolic risk in healthy 14- to 18-y-old adolescents. This trial was registered at clinicaltrials.gov as NCT02150122.",
keywords = "Faculty of Science, Vitamin D, Adolescents, Cardiovascular risk factors, Randomized controlled trial",
author = "Smith, {Taryn J} and Laura Tripkovic and Hanne Hauger and Damsgaard, {Camilla Trab} and Christian M{\o}lgaard and Lanham-New, {Susan A} and Hart, {Kathryn H}",
note = "CURIS 2018 NEXS 206",
year = "2018",
doi = "10.1093/jn/nxy079",
language = "English",
volume = "148",
pages = "1269--1275",
journal = "Journal of Nutrition",
issn = "0022-3166",
publisher = "American Society for Nutrition",
number = "8",

}

RIS

TY - JOUR

T1 - Winter cholecalciferol supplementation at 51°N has no effect on markers of cardiometabolic risk in healthy adolescents aged 14-18 years

AU - Smith, Taryn J

AU - Tripkovic, Laura

AU - Hauger, Hanne

AU - Damsgaard, Camilla Trab

AU - Mølgaard, Christian

AU - Lanham-New, Susan A

AU - Hart, Kathryn H

N1 - CURIS 2018 NEXS 206

PY - 2018

Y1 - 2018

N2 - Background: Epidemiologic studies have supported inverse associations between low serum 25-hydroxyvitamin D [25(OH)D] and cardiometabolic risk markers, but few randomized trials have investigated the effect of vitamin D supplementation on these markers in adolescents.Objective: The objective of this study was to investigate the effect of winter-time cholecalciferol (vitamin D3) supplementation on cardiometabolic risk markers in white, healthy 14- to 18-y-old adolescents in the UK (51°N) as part of the ODIN Project.Methods: In a dose-response trial, 110 adolescents (mean ± SD age: 15.9 ± 1.4 y; 43% male; 81% normal weight) were randomly assigned to receive 0, 10 or 20 μg/d vitamin D3 for 20 wk (October-March). Cardiometabolic risk markers including BMI-for-age z score (BMIz), waist circumference, systolic and diastolic blood pressure, fasting plasma triglycerides, cholesterol (total, HDL, LDL, and total:HDL), and glucose were measured at baseline and endpoint as secondary outcomes, together with serum 25(OH)D. Intervention effects were evaluated in linear regression models as between-group differences at endpoint, adjusted for the baseline value of the outcome variable and additionally for age, sex, Tanner stage, BMIz, and baseline serum 25(OH)D.Results: Mean ± SD baseline serum 25(OH)D was 49.1 ± 12.3 nmol/L and differed between groups at endpoint with concentrations of 30.7 ± 8.6, 56.6 ± 12.4, and 63.9 ± 10.6 nmol/L in the 0, 10, and 20 μg/d groups, respectively (P ≤ 0.001). Vitamin D3 supplementation had no effect on any of the cardiometabolic risk markers (all P > 0.05), except for lower HDL (-0.12 mmol/L; 95% CI: -0.21, 0.04 mmol/L; P = 0.003) and total cholesterol (-0.21 mmol/L; 95% CI: -0.42, 0.00 mmol/L; P = 0.05) in the 20 μg/d than in the 10 μg/d group, which disappeared in the fully adjusted analysis (P = 0.27 and P = 0.30, respectively).Conclusions: Supplementation with vitamin D3 at 10 and 20 μg/d, which increased serum 25(OH)D concentrations during the winter-time, had no effect on markers of cardiometabolic risk in healthy 14- to 18-y-old adolescents. This trial was registered at clinicaltrials.gov as NCT02150122.

AB - Background: Epidemiologic studies have supported inverse associations between low serum 25-hydroxyvitamin D [25(OH)D] and cardiometabolic risk markers, but few randomized trials have investigated the effect of vitamin D supplementation on these markers in adolescents.Objective: The objective of this study was to investigate the effect of winter-time cholecalciferol (vitamin D3) supplementation on cardiometabolic risk markers in white, healthy 14- to 18-y-old adolescents in the UK (51°N) as part of the ODIN Project.Methods: In a dose-response trial, 110 adolescents (mean ± SD age: 15.9 ± 1.4 y; 43% male; 81% normal weight) were randomly assigned to receive 0, 10 or 20 μg/d vitamin D3 for 20 wk (October-March). Cardiometabolic risk markers including BMI-for-age z score (BMIz), waist circumference, systolic and diastolic blood pressure, fasting plasma triglycerides, cholesterol (total, HDL, LDL, and total:HDL), and glucose were measured at baseline and endpoint as secondary outcomes, together with serum 25(OH)D. Intervention effects were evaluated in linear regression models as between-group differences at endpoint, adjusted for the baseline value of the outcome variable and additionally for age, sex, Tanner stage, BMIz, and baseline serum 25(OH)D.Results: Mean ± SD baseline serum 25(OH)D was 49.1 ± 12.3 nmol/L and differed between groups at endpoint with concentrations of 30.7 ± 8.6, 56.6 ± 12.4, and 63.9 ± 10.6 nmol/L in the 0, 10, and 20 μg/d groups, respectively (P ≤ 0.001). Vitamin D3 supplementation had no effect on any of the cardiometabolic risk markers (all P > 0.05), except for lower HDL (-0.12 mmol/L; 95% CI: -0.21, 0.04 mmol/L; P = 0.003) and total cholesterol (-0.21 mmol/L; 95% CI: -0.42, 0.00 mmol/L; P = 0.05) in the 20 μg/d than in the 10 μg/d group, which disappeared in the fully adjusted analysis (P = 0.27 and P = 0.30, respectively).Conclusions: Supplementation with vitamin D3 at 10 and 20 μg/d, which increased serum 25(OH)D concentrations during the winter-time, had no effect on markers of cardiometabolic risk in healthy 14- to 18-y-old adolescents. This trial was registered at clinicaltrials.gov as NCT02150122.

KW - Faculty of Science

KW - Vitamin D

KW - Adolescents

KW - Cardiovascular risk factors

KW - Randomized controlled trial

U2 - 10.1093/jn/nxy079

DO - 10.1093/jn/nxy079

M3 - Journal article

C2 - 29920594

VL - 148

SP - 1269

EP - 1275

JO - Journal of Nutrition

JF - Journal of Nutrition

SN - 0022-3166

IS - 8

ER -

ID: 198226960